Phase 1 / 2 Double-Masked Randomized Vehicle-Controlled Study H-1337 Ophthalmic Solution in Glaucoma and Ocular Hypertension.

[1]  R. Casson.  Medical therapy for glaucoma: A review , 2022, Clinical & experimental ophthalmology.

[2]  Terry Kim,et al.  Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). , 2019, American journal of ophthalmology.

[3]  C. Bunce,et al.  Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial , 2019, The Lancet.

[4]  H. Hidaka,et al.  Isoquinoline sulfonamides such as fasudil, H-1152, ripasudil and H-1129 produce IOP-lowering and neuroprotective effects through Rho kinase inhibition , 2018 .

[5]  G. Novack,et al.  Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). , 2018, American journal of ophthalmology.

[6]  M. Araie,et al.  Efficacy and safety of SNJ‐1656 in primary open‐angle glaucoma or ocular hypertension , 2015, Acta ophthalmologica.

[7]  M. Araie,et al.  Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. , 2015, JAMA ophthalmology.

[8]  H. Hidaka,et al.  A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP , 2015 .

[9]  H. Hidaka,et al.  Elucidation of molecular mechanism of H-1337, an anti-glaucoma agent , 2015 .

[10]  H. Hidaka,et al.  IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys. , 2014, Bioorganic & medicinal chemistry letters.

[11]  M. Araie,et al.  Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. , 2013, JAMA ophthalmology.

[12]  G. Novack,et al.  Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension , 2013 .

[13]  G. Novack,et al.  Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. , 2011, American journal of ophthalmology.

[14]  Young H. Kwon,et al.  Primary open-angle glaucoma. , 2009, The New England journal of medicine.

[15]  M. Sherwood,et al.  Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. , 2006, Archives of ophthalmology.

[16]  M. Araie,et al.  A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients , 2004, Eye.

[17]  Y. Kitazawa,et al.  Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[18]  S. Kawamoto,et al.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. , 1984, Biochemistry.